Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the ECC Webcasts. By clicking the button below you are declaring and confirming that you are a healthcare professional.

You are here

Advances in Targeted Treatment for BRAF V600-Mutant Metastatic Melanoma: Evidence-based Combination Strategies (AV)

Date: Mon. 28 Sept / 13:00 – 14:30 / Hall A4

Treatments for BRAF V600-mutant melanoma have changed dramatically including the development of combination therapies which target both BRAF and MEK. This session explores the potential benefits of dual BRAF/MEK inhibition combination therapy targeting both the oncologic driver and a downstream signalling component within the MAPK pathway through a review of the clinical evidence and real-world data as well as an exploration of patient case studies. 

This Webcast and Webcast Report were supported by Novartis Oncology, all items are subject to independent peer and editorial review. 


Presentations

Search this site

Search form

E-Alert

Register to our E-Alert to stay informed of new clinical research and cases published on this platform.

Share